Susan Collins actually said...

"Clinical holds can be an important and appropriate tool for the Agency to utilize when a potential concern with an application has surfaced, but they are not a substitute for timely, constructive, and..."

"I am concerned that the lack of face-to-face meetings may be negatively affecting the FDA's ability to keep pace and retain its scientific and regulatory stature as the gold standard."

"What does all this mean for the delivery of assistance to women and girls in Afghanistan? Are we really going to be able to reach them?"

"My concern is this: is that money really going to get to women and children?"